Answers are grounded in this paper and cite their sources.
We studied 14 patients acutely infected with wild-type HIV, who underwent supervised treatment interruptions after initial antiretroviral treatment including lamivudine. Lamivudine resistance mutations emerged for the first time during supervised treatment interruptions in one patient. Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted. Supervised treatment interruptions after highly active antiretroviral therapy for symptomatic primary HIV-1 infection have resulted in improved immune responses and at least a transient control of viremia [1]. However, lamivudine-resistant mutants were recently found to emerge in blood during supervised treatment interruptions in chronically infected patients who had previous lamivudine failure [2]. We evaluated whether drug resistance might also emerge in blood during supervised treatment interruptions after the first antiretroviral treatment in patients acutely infected with wild-type HIV. Methods Fourteen patients were treated with protease inhibitor-containing triple-combination regimens including lamivudine before, or at the time of, HIV-1 seroconversion in an institutional review board-approved trial [1]. Each was successfully treated for at least 8 months before simultaneously discontinuing all drugs. HIV-1 pol genes were sequenced from plasma collected at the first visit when the viral load was greater than 1000 copies/ml of HIV-1 RNA (Roche Amplicor Ultrasensitive, Roche Diagnostics, Indianapolis, IN, USA) during supervised treatment interruptions. Sequences were also obtained from additional plasma specimens from one subject, as well as from replication-competent virus cultured from peripheral blood mononuclear cells (PBMC) that were depleted of CD8 T lymphocytes [3], and from amplicons directly amplified from the DNA of circulating PBMC. Polymerase chain reaction (PCR) amplifications (XL, PE) were from plasma RNA, RNA from supernatants of enhanced cultures of PBMC [3], or patient PBMC DNA (Puregene, Gentra, Minneapolis, MN, USA) [4]. Some PCR products were cloned (Clone AMP, Gibco-BRL, Rockville, MD, USA; and TA cloning, Invitrogen, Carlsbad, CA, USA). The sequencing of clones used ABI 377 (BigDye, PE Biosystems and Sequencher 3.1, Gene Codes, Ann Arbor, MI, USA). Population sequencing used TrueGene (v3.1.3, RUO; VGI, Suwanee, GA, USA) or ViroSeq (v2; AB, Foster City, CA, USA). All sequencing was retrospective. Results Each subject had a wild-type HIV-1 pol population sequence from plasma HIV-1 RNA at the pre-treatment baseline. Subjects were treated for a mean of 525 days before supervised treatment interruption. The mean time to viral suppression during initial therapy was 218 days. Sequence was obtained from a time early during the supervised treatment interruption when plasma HIV-1-RNA levels first reached at least 1000 copies/ml in each subject. The plasma specimens from six subjects were screened by sequencing from only the first supervised treatment interruption, five from two supervised treatment interruptions, and three from three supervised treatment interruptions. Resistance was first detected in the initial supervised treatment interruption specimen with more than 1000 copies/ml from only one subject (AC-25), who was studied further. A mixture of mutants RT 184I and V, along with the wild-type M184, were identified in AC-25's screening specimen (see Table 1).Table 1: Characteristics of subjects and treatments.Subject AC-25's treatment history, viral loads and genotypes are detailed chronologically (Table 2). Five sequences before, and soon after, starting therapy had only wild-type pol with three different sequencing methodologies. The plasma HIV-1-RNA level was suppressed below 400 copies/ml by 125 days of initiating therapy. Lamivudine was continued, but zidovudine and nelfinavir were switched to stavudine and indinavir on day 125 because of fatigue and anemia. Between days 268 and 462, the plasma HIV-1-RNA level was less than 50 copies/ml (Table 2). Self-report, pill counts, and prescription records corroborated excellent adherence.Table 2: Subject AC-25: longitudinal HIV-1 genotypic analysis. P12607After 15 months of treatment, including more than 11 months of viral load suppression, treatment was discontinued. Fourteen days after treatment was interrupted for the first time, the plasma HIV-1-RNA level became detectable at 142 copies/ml. Plasma (4 ml) from supervised treatment interruption no. 1 on day 14 was centrifuged, PCR amplified, and pol PCR products were cloned. Clonal sequence analysis identified the lamivudine resistance mutation RT M184V in one of 13 clones. Wild-type virus was detected at day 17, and on day 21 a mixture of 184 M/I/V was apparent in the screening population sequence. After 38 days off-therapy during supervised treatment interruption no. 1, subject 25 restarted efavirenz, didanosine and abacavir (treatment period 2). Different drugs were used for two reasons: facial and limb lipoatrophy and peripheral neuropathy. Only wild-type virus was detected when viremia was diminishing, but RT M184V was repeatedly detectable again when treatment was later discontinued for the second supervised treatment interruption. Treatment was later re-started with abacavir, tenofovir, and efavirenz, and the HIV-1-RNA level was again suppressed to less than 50 copies/ml. Discussion In this study of patients with treated acute HIV infection undergoing supervised treatment interruptions, one subject developed a detectable resistance mutation, in this case to lamivudine. In that subject, only wild-type virus was detected before treatment and for over 462 days of treatment, However, at 14 days after therapy was initially interrupted, a lamivudine-selected RT 184 mutant was detected in one of 13 clones, and later became the dominant species. This suggests the emergence of resistance during the period of enhanced viral replication coincident with declining plasma drug levels. A mixture including RT 184 I, V, and M was detected in plasma RNA on day 21 of supervised treatment interruption no. 1. This detection of both RT 184I and V mutants before the more consistent detection of only RT 184V is consistent with newly emerging resistance. Earlier reports documented that lamivudine initially selects for both RT 184I (ATA) and 184V (GTG) mutants as separately evolved variants from the wild-type (ATG) [5,6]. This suggests that the selection of lamivudine resistance began in the first few days after AC-25 stopped the drug. Intracellular levels of lamivudine may have persisted longer than the other drugs in the regimen. The fact that this resistance was observed in only one of 14 patients may reflect differences in intracellular pharmacokinetics. Other data suggest a variation among individuals in the intracellular pharmacokinetics of lamivudine triphosphate, with a median half-life of 15 h, ranging from 6 to 32 h in different individuals [7]. Mutants may have been selected only in the first few days after stopping drugs, and may not become detectable until after the viral load increased. An alternative hypothesis involves selection of the mutant within tissues when the lamivudine-containing combination regimen was still being given, and not in blood. The lack of detection of a mutation in PBMC DNA on days 3 and 17 of the first supervised treatment interruption (and from any virus cultured from CD8 lymphocyte-depleted PBMC) is consistent either with recent emergence of the resistant mutant de novo in blood, or the origin of the mutant earlier during initial therapy from an archive other than circulating blood cells. Lack of detection of the mutant in some plasma specimens duriuring treatment period 2 (days 10, 18, and 244, Table 2) may have been caused by technical limitations related to low viral loads. However, this could also be explained by more rapid suppression in the unidentified non-blood compartment where mutants originated, as documented for cervicovaginal HIV-1 [8,9]. The development of drug resistance during supervised treatment interruptions has been demonstrated previously in chronically infected individuals in whom an earlier lamivudine-containing drug regimen had failed [2]. In the current study, resistance emerged during supervised treatment interruption in one of 14 subjects treated very early after acquiring wild-type HIV-1. Subject AC-25 was studied more intensively than the others. Therefore, we cannot exclude the possibility of undetected mutants in other subjects. Our observation underscores the need to monitor resistance closely in supervised treatment interruption trials, and to study drug selection in cellular compartments.
No takes yet. Share an insight, caveat, or question.
Tremblay et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: